A retrospective case note review of the neonatal death of infants born to women living with HIV in the UK and Ireland 1998-2017 Helen Yan, Helen Peters, Claire Thorne

Population, Policy and Practice Research and Teaching Department, UCL Great Ormond Street Institute of Child Health

Background

- Successful prevention strategies have driven the decline of the vertical transmission (VT) rate in the UK/Ireland from 2.1% in 2000-2001 to 0.28% in 2015-2016 [Figure 1].
- However, HIV-exposed uninfected children have been shown to be at increased risk of other adverse outcomes, particularly in the first few years of life.
- There is need for increased understanding into outcomes such as

Methods


National Surveillance of HIV in Pregnancy and Childhood (NSHPC) is part of Public Health England's Infectious Diseases in Pregnancy Screening Programme.

All pregnancies to women living with HIV in the UK/Ireland are actively reported, along with their HIV-exposed infants and any children diagnosed with HIV (<16years).

Completeness is estimated at >95%.

neonatal death (NND) in infants born to women living with HIV (WLWH).

Figure 1: Vertical transmission rates of HIV among diagnosed women 2000-16



- Eligible population: live-birth deliveries to diagnosed women in 1998-2017.
- Neonatal death was defined as a live-born baby, who died before 28 completed days after birth
- Estimated yearly incidence of NND was reported for 1998-2017 and causes of NND coded using WHO ICD-PM classification.
- **Risk factor analysis used multivariable logistic regression**, including delivery year, maternal origin, maternal age, delivery CD4 count and viral load, antiretroviral therapy (ART) at conception, injecting drug use (IDU) and infant sex.
- A second analysis restricted to the years 2007-2017 was carried out, reflecting a time of improved reporting of delivery viral load.

Results

- **20,012 live-born infants born to 12,684 WLWH** in 1998-2017.
- Median maternal age at delivery was 31 years (IQR 27-35); other maternal characteristics are shown in Table 1.
- The overall NND rate was 4.1 per 1000 live-births (95% CI, 3.2-5.0), compared to an average of 3.24 in the general population (1998-2016).

Figure 2. Mosaic plot of causes of neonatal death (WHO ICD-PM classification) by primary, secondary and other causes of death[#]




Table 1: Maternal and pregnancy characteristics

Characteristic	N (%)
Maternal region of origin	n=19385
Africa	14546 (75)
UK/Ireland	2917 (15)
Other	1922 (10)
Timing of diagnosis	n=19601
Before pregnancy	13469 (69)
During pregnancy	6132 (31)
ART at conception	n=18780
Yes	7836 (42)
No	10944 (58)
Viral load (copies/ml) at delivery	n=11352
<50	8663 (76)
≥50	2689 (24)

- 82 NNDs in total (18 [22%] without reported cause of death).
- 26 (32%) NNDs occurred within the first day of life (day 0).
- **104 individual causes of death** were reported among remaining 64 NND cases [Figure 2].
- **Prematurity** was the leading cause of death, reported in 44% (28/64)

[#]Area of each coloured block indicates relative frequency of each observation)

Risk factor analysis 1998-2017

- Only factor significantly associated with NND risk was ART at conception
 - Adjusted odds ratio (AOR) 0.57 (95% CI 0.30-0.99)

Restricted analysis (including delivery viral load 2007-2017)

Delivery year (AOR 1.18 [95% CI 1.03-1.34] per 1 year increase) and detectable viral load (i.e. >50 copies/ml) (AOR 8.14 [95% CI 3.46-19.17] vs undetectable) were associated with increased NND risk

cases, followed by **congenital abnormality** reported in 22 cases (34%)

Most common abnormality was Trisomy 18 (6 cases)

Conclusions

- WLWH had a higher NND rate than the general population
- **Detectable viral load** and **increasing calendar year** were associated with increased risk and **ART use at conception** with decreased risk of NND
- Main cause of NND was preterm delivery

- Other AORs (all non statistically significant)
 - Maternal age \geq 40 vs 24-39 years = 1.40 (95% CI 0.54-3.58)
 - Maternal IDU vs no IDU = 2.97 (95% CI 0.78-11.3)
 - CD4 <350 cells/mm³ vs \geq 350 = 1.47 (95% CI 0.96-2.69)
- Limitations included lack of data on maternal substance use and weight, and lack of cause of death in 22% of cases
- Wide 95% CIs observed reflected small numbers of NNDs.
- Promotion of maternal viral load suppression through effective **ART** will not only **improve maternal health and prevent VT**, but may also **reduce NND**. The NSHPC continues to monitor NNDs.



Funding and ethics

The NSHPC is part of the Integrated Screening Outcomes Surveillance Service (ISOSS) funded from Public Health England's Infectious Diseases in Pregnancy Screening (IDPS) Programme and operates with Regulation 3 approval.

Acknowledgements

Many thanks to everyone who reports to the NSHPC, the current NSHPC and ISOSS team, and the IDPS team headed by Sharon Webb. Any views expressed are those of the authors and not necessarily those of the funders.



